Biology subjects

Raynal, F.

Publications and source records attributed to Raynal, F..

6 recordsLinked to original sources

bioRxiv2025

Targeting human M2 macrophages with antibodies in optimized 3D tumor spheroids

Tumor microenvironment (TME) constituents, including tumor-associated macrophages (TAMs), are now well known to have a significant impact on tumor development. TAMs can be predominant cells in the TME, able to promote cancer cell proliferation, resistance to treatments and immunosuppression. Inactivating these TAMs in tumors by their depletion or their repolarization into a specific anti-tumor, inflammatory phenotype constitutes a significant challenge in immuno-oncology. Several tools and methods to target TAMs have been proposed but they often show low specificity for pro-tumoral macrophages and target myeloid cells too broadly. This research area is therefore in full expansion and warrants the development of appropriate study models. Given the current global effort to reduce the use of in vivo approaches, developing in vitro models that mimic the behavior of TAMs in the TME has become a priority. In this study, we focused on targeting pro-tumoral TAMs in a simple in vitro model recapitulating cancer cell proliferation and TAMs specific phenotype. We developed a 3D model consisting of cancer cells and pro-tumoral macrophages, in which these macrophages promote tumor cell proliferation, maintaining an immunosuppressive phenotype. We showed that, in this model, macrophages can be easily targeted and killed with specific antibodies even in the central regions of the spheroid. This model could be a first in vitro approach to screen new TAM depletion or depolarization tools before application in in vivo models.

cancer biology↗

bioRxiv2025

Time-series RNA-Seq and data-driven network inference unveil dynamics of cell activation, survival and crosstalk in Chronic Lymphocytic Leukaemia in vitro models

How do cancer cells respond to their environment, and what are the key regulators behind their behaviour? While immune cell reprogramming in the tumour microenvironment (TME) has been extensively studied, the dynamic regulatory changes within cancer cells in response to interactions with immune cells remain poorly understood. In Chronic Lymphocytic Leukaemia (CLL), this knowledge gap limits our ability to fully grasp the disease progression and to design effective, personalised interventions. To tackle this, we combine time-series transcriptomics with data-driven gene regulatory network (GRN) inference to uncover the temporal regulatory mechanisms driving CLL cell behaviour within a reconstituted in vitro TME. Using cultures of peripheral blood from CLL patients or of purified patient-derived CLL cells, we profile gene expression across five time points spanning 14 days under these experimental conditions. By inferring GRNs from transcription factor activity, we capture patient-specific and temporally resolved regulatory interactions that highlight how immune signals shape cancer cell phenotypic changes. Our network analysis reveals distinct gene modules associated with critical processes such as cytokine signalling, metabolic reprogramming and differentiation, hallmarks of immune-cancer cell interaction. Intriguingly, we found that while the presence of immune cells in the environment significantly alters CLL cell activation, their survival trajectories are predominantly governed by intrinsic features. This study not only offers mechanistic insights into how immune cell presence influences CLL cell fate but also presents a robust computational framework for integrating time-series transcriptomics with GRN inference, which can then be used to study the long-term behaviour of the CLL cells through dynamical modelling.

systems biology↗

bioRxiv2023

Chromatin network rearrangements in differentiation and cancer reveal connections between evolutionary processes and gene regulation

Cancer cells are highly plastic, allowing them to adapt to changing conditions. Genes related to basic cellular processes evolved in ancient species, while more specialized genes appeared later with multicellularity (metazoan genes) or even after mammals evolved. Transcriptomic analyses have shown that ancient genes are up-regulated in cancer, while metazoan-origin genes are inactivated. Despite the importance of these observations, the underlying mechanisms remain unexplored. Here, we study local and global epigenomic mechanisms that may regulate genes from specific evolutionary periods. Using evolutionary gene age data, we characterize the epigenomic landscape, gene expression regulation, and chromatin organization in three cell types: human embryonic stem cells, normal B-cells, and primary cells from Chronic Lymphocytic Leukemia, a B-cell malignancy. We identify topological changes in chromatin organization during differentiation observing patterns in Polycomb repression and RNA Polymerase II pausing, which are reversed during oncogenesis. Beyond the non-random organization of genes and chromatin features in the 3D epigenome, we suggest that these patterns lead to preferential interactions among ancient, intermediate, and recent genes, mediated by RNA Polymerase II, Polycomb, and the lamina, respectively. Our findings shed light on gene regulation according to evolutionary age and suggest this organization changes across differentiation and oncogenesis.

cancer biology↗

bioRxiv2023

Enhancer-driven local 3D chromatin domain folding modulates transcription in human mammary tumor cells

The genome is organized in functional compartments and structural domains at the sub-megabase scale. How within these domains interactions between numerous cis-acting enhancers and promoters regulate transcription remains an open question. Here, we determined chromatin folding and composition over several hundred kb around estrogen responsive genes in human breast cancer cell lines following hormone stimulation. Modeling of 5C data at 1.8 kb resolution was combined with quantitative 3D analysis of multicolor FISH measurements at 100 nm resolution and integrated with ChIP-seq data on transcription factor binding and histone modifications. We found that rapid estradiol induction of the progesterone gene (PGR) expression occurs in the context of pre-existing, cell type specific chromosomal architectures encompassing the 90 kb PGR coding region and an enhancer-spiked 5 300 kb upstream genomic region. In response to estradiol, interactions between estrogen-receptor (ER) bound regulatory elements are re-enforced. While initial enhancer - gene contacts coincide with RNA Pol 2 binding and transcription initiation, sustained hormone stimulation promotes ER accumulation creating a regulatory hub stimulating transcript synthesis. In addition to implications for estrogen receptor signaling, we uncover that preestablished chromatin architectures efficiently regulate gene expression upon stimulation without the need for de-novo extensive rewiring of long-range chromatin interactions.

cell biology↗

bioRxiv2020

A Boolean Model of the Formation of Tumour Associated Macrophages in an in-vitro Model of Chronic Lymphocytic Leukaemia

The tumour microenvironment is the collection of cells in and surrounding cancer cells in a tumour including a variety of immune cells, especially neutrophils and monocyte-derived macrophages. In a tumour setting, macrophages encompass a spectrum between a tumour-suppressive (M1) or tumour-promoting (M2) state. The biology of macrophages found in tumours (Tumour Associated Macrophages) remains unclear, but understanding their impact on tumour progression is highly important. In this paper, we perform a comprehensive analysis of a macrophage polarization network, following two lines of enquiry: (i) we reconstruct the macrophage polarization network based on literature, extending it to include important stimuli in a tumour setting, and (ii) we build a dynamical model able to reproduce macrophage polarization in the presence of different stimuli, including the contact with cancer cells. Our simulations recapitulate the documented macrophage phenotypes and their dependencies on specific receptors and transcription factors, while also elucidating the formation of a special type of tumour associated macrophages in an in-vitro model of chronic lymphocytic leukaemia. This model constitutes the first step towards elucidating the cross-talk between immune and cancer cells inside tumours, with the ultimate goal of identifying new therapeutic targets that could control the formation of tumour associated macrophages in patients.

systems biology↗

bioRxiv2020

The histone variant macroH2A1.1 regulates gene expression by direct association with their transcription start site.

The histone variant macroH2A1.1 (mH2A1.1) plays a role in cancer development and metastasis-related processes. To determine the underlying molecular mechanisms, we mapped genome-wide localization of endogenous mH2A1.1 in the human breast cancer cell MDA-MB 231. We demonstrate that mH2A1.1 specifically binds to active promoters and enhancers in addition to facultative heterochromatin. Selective knock-down of mH2A1.1 deregulates expression of hundreds of highly active genes. Depending on the chromatin landscape, mH2A1.1 acts through two distinct molecular mechanisms. The first is to limit excessive transcription in a predefined environment and relies on domain recruitment of mH2A1.1 at the promoter and gene body. The second mechanism is specific to RNA Pol II (Pol II) paused genes. It requires recruitment of mH2A1.1 restricted to the TSS of these genes. Moreover, we show that these processes occur in a predefined local 3D genome organization and are largely independent of enhancer-promoter looping. Among the genes activated by mH2A1.1, genes regulating mammary tumor cell migration are mostly dependent on Pol II release for their expression level, unlike other categories of mH2A1.1-regulated genes. We thus identified an intriguing new mode of transcriptional regulation by mH2A1.1 and propose that mH2A1.1 serves as a transcriptional modulator with a potential role in assisting the conversion of promoter-locked RNA polymerase II into a productive and elongated Pol II.

genomics↗